Related Experiment Video

Updated: May 24, 2025

Isolation of Primary Cancer-Associated Fibroblasts from a Syngeneic Murine Model of Breast Cancer for the Study of Targeted Nanoparticles
08:02

Isolation of Primary Cancer-Associated Fibroblasts from a Syngeneic Murine Model of Breast Cancer for the Study of Targeted Nanoparticles

Published on: May 14, 2021

5.5K

Impact of targeting the platelet-activating factor and its receptor in cancer treatment

Kimya Qaderi1, Arvin Shahmoradi2, Anita Thyagarajan3

  • 1Department of Molecular and Cell Biology, College of Life Sciences, University of Leicester, University Road, Leicester, LE1 7RH, UK.

Military Medical Research
|March 3, 2025
PubMed

Insights

Targeting platelet-activating factor (PAF) and its receptor (PAFR) signaling is a promising cancer treatment strategy. PAF/PAFR antagonists show effectiveness and synergistic effects with chemotherapy and radiation therapy in preclinical cancer models.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Platelet-activating factor (PAF) and its receptor (PAFR) signaling are implicated in cancer progression, including growth and metastasis.
  • PAFR's interaction with oncogenic pathways makes it a potential therapeutic target for cancer treatment.

Purpose of the Study:

  • To review the evidence for PAF/PAFR signaling in cancer.
  • To highlight the efficacy of PAF and PAFR inhibitors and antagonists in various cancer models.
  • To discuss the synergistic effects of these antagonists with standard cancer therapies.

Main Methods:

  • Comprehensive literature review of studies investigating PAF/PAFR signaling in cancer.
  • Analysis of data from preclinical cancer models treated with PAF/PAFR antagonists.
  • Evaluation of studies examining combination therapies involving PAF/PAFR antagonists.

Main Results:

  • Various classes of PAF and PAFR inhibitors/antagonists demonstrate effectiveness against multiple cancer types in experimental models.
  • PAF/PAFR antagonists exhibit synergistic effects when combined with chemotherapy and radiation therapy.
  • Targeting the PAF/PAFR axis shows significant potential in enhancing anti-cancer treatment efficacy.

Conclusions:

  • The PAF/PAFR signaling pathway is a viable target for novel cancer therapies.
  • PAF/PAFR antagonists represent a promising therapeutic strategy, particularly in combination with chemotherapy and radiotherapy.
  • Further research into PAF/PAFR-targeted therapies could lead to improved cancer treatment outcomes.
Keywords:
AntagonistsCancerCell signaling pathwaysChemotherapyInhibitorsPlatelet-activating factor (PAF)Platelet-activating factor-receptor (PAFR)Radiation therapy

More Related Videos

Phospholipid Mediator Induced Transformation in Three-Dimensional Cultures08:02

Phospholipid Mediator Induced Transformation in Three-Dimensional Cultures

Published on: July 27, 2022

2.4K
Flow Cytometry Analysis of Tissue Factor Expression in Human Platelets10:08

Flow Cytometry Analysis of Tissue Factor Expression in Human Platelets

Published on: November 22, 2024

428

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
2.3K
Intracellular Signaling Affects Focal Adhesions01:17

Intracellular Signaling Affects Focal Adhesions

Integrins act both as extracellular input receivers and as intracellular processing activators. As their name suggests, integrins are entirely integrated into the membrane structure. Their hydrophobic membrane-spanning regions interact with the phospholipid bilayer's hydrophobic region. These membrane receptors provide extracellular attachment sites for effectors like hormones and growth factors. They activate intracellular response cascades when their effectors are bound and active.
Some...
2.5K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
126